SHORT COMMUNICATION

Effect of a p38 MAPK inhibitor on FFA-induced hepatic insulin resistance in vivo

S Pereira1,7, WQ Yu1,7, J Moore2, Y Mori1,3, E Tsiani2 and A Giacca1,4,5,6

The mechanisms whereby prolonged plasma free fatty acids elevation, as found in obesity, causes hepatic insulin resistance are not fully clarified. We herein investigated whether inhibition of p38 mitogen-activated protein kinase (MAPK) prevented hepatic insulin resistance following prolonged lipid infusion. Chronically cannulated rats were subdivided into one of four intravenous (i.v.) treatments that lasted 48 h: Saline (5.5 μl min⁻¹), Intralipid plus heparin (IH, 20% Intralipid+20 U ml⁻¹ heparin; 5.5 μl min⁻¹), IH+p38 MAPK inhibitor (SB239063) and SB239063 alone. During the last 2 h of treatment, a hyperinsulinemic (5 mU kg⁻¹ min⁻¹) euglycemic clamp together with [3–³H] glucose methodology was carried out to distinguish hepatic from peripheral insulin sensitivity. We found that SB239063 prevented IH-induced hepatic insulin resistance, but not peripheral insulin resistance. SB239063 also prevented IH-induced phosphorylation of activating transcription factor 2 (ATF2), a marker of p38 MAPK activity, in the liver. Moreover, in another lipid infusion model in mice, SB239063 prevented hepatic but not peripheral insulin resistance caused by 48 h combined ethyloleate plus ethylpalmitate infusion. Our results suggest that inhibition of p38 MAPK may be a useful strategy in alleviating hepatic insulin resistance in obesity-associated disorders.

 INTRODUCTION

Elevated plasma free fatty acids (FFAs), as found in obesity, induce hepatic insulin resistance. Prolonged exposure of hepatocytes to FFAs activates p38 mitogen-activated protein kinase (MAPK), which decreases the ability of insulin to reduce gluconeogenesis. In murine models of obesity, hepatic p38 MAPK is activated and when p38 MAPK is overexpressed in the liver, impairment of insulin signalling ensues. Nevertheless, the role of p38 MAPK in FFA-induced hepatic insulin resistance in vivo has not been assessed. We herein used prolonged (48 h) lipid infusion, namely Intralipid plus heparin (IH) infusion in rats and combined ethyloleate plus ethylpalmitate infusion in mice, to elevate plasma FFAs because thus far, p38 MAPK activation has been associated with prolonged in vitro exposure to FFAs or obesity-associated insulin resistance, a chronic model of FFA elevation. We have found that protein kinase C (PKC)-δ is activated in the liver after prolonged lipid infusion, and studies in hepatocytes have shown that PKC-δ activates p38 MAPK. Hence, in the current study we used a p38 MAPK inhibitor to determine whether it prevented hepatic insulin resistance caused by prolonged plasma FFA elevation.

MATERIALS AND METHODS

Experiments

The Animal Care Committee of the University of Toronto approved all procedures, which were in accordance with the Canadian Council of Animal Care Standards. Chronically cannulated female Wistar rats were randomized in a non-blinded manner into one of four intravenous (i.v.) treatments: Saline (SAL, 5.5 μl min⁻¹), IH (20% Intralipid+20 U ml⁻¹ heparin; 5.5 μl min⁻¹), IH+p38 MAPK inhibitor SB239063 (SB, Sigma, St Louis, MO, USA); 2.25 mg kg⁻¹ h⁻¹ for first hour and 0.55 mg kg⁻¹ h⁻¹ thereafter) and SB alone. After an overnight fast, at 44 h of treatment, [³H] glucose was started (8 μCi bolus plus 0.15 μCi min⁻¹). A 2-h hyperinsulinemic (insulin infusion: 5 mU kg⁻¹ min⁻¹) euglycemic clamp was initiated at 46 h. Blood samples for plasma assays were collected during the basal period (30 min before the clamp) and during the last 30 min of the clamp. For western blot analysis, the liver was collected under anesthesia after 48 h of infusions.

Male C57BL6 mice underwent a hyperinsulinemic (5 mU kg⁻¹ min⁻¹) euglycemic clamp with [³H] glucose at the end of 48 h infusion of ethanol control in glycerol vehicle (EtOH, 0.12 μmol min⁻¹) or combined ethyloleate+ethylpalmitate infusion in a 2:1 ratio in glycerol vehicle (EtO/P, total dose: 0.12 μmol min⁻¹) or EtO/P+SB (4.5 mg kg⁻¹ h⁻¹ during the first hour, 1.1 mg kg⁻¹ h⁻¹ thereafter). This lipid infusion method is based on the conversion of ethyl fatty acids to fatty acids and ethanol by plasma esterases.

Assays and calculations

Measurements of plasma glucose, insulin and FFA and calculations of glucose kinetics were performed as reported previously. For western blots, cytosolic fractions or whole homogenates of liver samples were prepared. The primary antibody for total activating transcription factor 2 (ATF2) was from Santa Cruz Biotechnology (Santa Cruz, CA, USA; cat # sc-187), while the rest of the primary antibodies were from Cell Signaling Technology.

1Department of Physiology, University of Toronto, Toronto, ON, Canada; 2Department of Health Sciences, Brock University, St Catharines, ON, Canada; 3Department of Medicine, Showa University School of Medicine, Shinagawa, Tokyo, Japan; 4Department of Medicine, University of Toronto, Toronto, ON, Canada; 5Institute of Medical Science, University of Toronto, Toronto, ON, Canada and 6Banting and Best Diabetes Centre, University of Toronto, Toronto, ON, Canada. Correspondence: Dr A Giacca, Department of Physiology, University of Toronto, Medical Sciences Building, Room 3336, 1 King’s College Circle, Toronto, ON, Canada M5S 1A8.

E-mail: adria.giacca@utoronto.ca

These authors contributed equally to this work.

Received 25 April 2015; revised 11 February 2016; accepted 21 February 2016
primary antibodies used were from Cell Signaling Technology (Danvers, MA, USA; cat #9221, 9251, 9252, 9271, 9272).

Statistics
Data are means ± s.e.m. Significance was accepted when $P < 0.05$. One-way ANOVA followed by Tukey’s t-test was used, unless further specified. Sample size was based on variances obtained in our previous studies using this model and is described in figure legends. Variances were similar across groups.

RESULTS
Plasma glucose was not different among groups during the basal (SAL: 6.60 ± 0.18 mM; $n = 7$; IH: 6.06 ± 0.22, $n = 8$; IH+SB: 5.77 ± 0.39, $n = 6$; SB: 6.66 ± 0.06, $n = 5$) and clamp periods (SAL: 6.40 ± 0.20; IH: 6.06 ± 0.28; IH+SB: 5.83 ± 0.39; SB: 6.49 ± 0.06). Basal plasma FFAs were ~2-fold higher ($P < 0.05$) in IH-infused groups (SAL: 472 ± 31 μM; IH: 894 ± 62; IH+SB: 1105 ± 103; SB: 557 ± 85). During the hyperinsulinemic clamp, FFAs were lower than basal as expected but remained elevated ($P < 0.05$) in IH-infused groups (SAL: 110 ± 23 μM; IH: 549 ± 70; IH+SB: 514 ± 67; SB: 176 ± 38). There was no intergroup difference in basal (SAL: 67 ± 12 pM; IH: 102 ± 20; IH+SB: 118 ± 32; SB: 119 ± 39) or clamp plasma insulin (SAL: 506 ± 29 pM; IH: 522 ± 25; IH+SB: 569 ± 58; SB: 557 ± 59).

There was a trend for IH to increase basal endogenous glucose production, which did not reach significance (Figure 1a) and was abolished by SB. IH elevated endogenous glucose production during the clamp and SB prevented this elevation (Figure 1a). Insulin-induced suppression of endogenous glucose production (that is, hepatic insulin sensitivity) was blunted by IH and rescued by SB (Figure 1b). Glucose infusion rate and glucose utilization were higher ($P < 0.05$) in SAL (27.0 ± 1.3 mg kg$^{-1}$min$^{-1}$ and

Figure 1. (a) Endogenous glucose production during basal and clamp periods. (b) Percent suppression of endogenous glucose production by insulin. (c) Percent augmentation of glucose utilization by insulin. (d) Protein content of phosphorylated ATF2 (p-ATF2) relative to total ATF2 in liver cytosolic fractions and representative blots of protein content of p-ATF2 relative to total (t) ATF2 in cytosolic fractions and whole liver homogenates (Wh hom; performed to confirm the initial results in cytosolic fractions). (e) Protein content of phosphorylated c-jun N-terminal kinase (p-JNK) relative to total JNK in whole liver homogenates. (f) Protein content of p-Akt relative to total Akt in whole liver homogenates. Liver tissue collected after 48 h of treatment infusion without the hyperinsulinemic euglycemic clamp was used for (d, e). For (f), liver tissue collected after 48 h of treatment infusion and hyperinsulinemic euglycemic clamp was used. Data are means ± s.e.m. Treatments: SAL, Saline; IH, Intralipid plus heparin; IH+SB, IH plus SB239063 (p38 MAPK inhibitor); SB, SB239063. For (a–c), $n = 7$ for SAL, $n = 8$ for IH, $n = 6$ for IH+SB and $n = 5$ for SB. For (d), $n = 5$ for SAL, $n = 4$ for IH, $n = 5$ for IH+SB and $n = 3$ for SB. For (e), $n = 4$ for SAL, IH and IH+SB, and $n = 3$ for SB. For (f), $n = 4$ for SAL, $n = 5$ for IH, $n = 4$ for IH+SB and $n = 4$ for SB. *$P < 0.05$ vs SAL. †$P < 0.05$ vs other groups. ‡$P < 0.05$ vs IH.
measures two-way ANOVA followed by Tukey’s t-test were used; \( p < 0.05 \) for clamp vs basal for a given treatment. \( n = 6 \) for ETH, \( n = 5 \) for ETH/P and \( n = 3 \) for ETH/P+SB.

MAPK is activated in muscle of humans with type 2 diabetes,10,11 activation of hepatic JNK was not altered by IH or SB239063. \( p38 \) increases gluconeogenic gene transcription,6 which may explain the increment in hepatic Akt activation. FFA-induced p38 MAPK activation also shows that the p38 MAPK inhibitor prevents IH-induced impairment downstream of phosphoinositide 3-kinase and the current study demonstrates that SB239063 inhibits both p38 MAPK, which suggests that SB239063 acts by inhibiting p38 MAPK.

As a marker of p38 MAPK activity, we determined the phosphorylation of its direct target ATF2 in liver tissues collected after 48 h of infusions, without hyperinsulinemic clamps because members of the MAPK family can be activated by insulin. IH increased ATF2 phosphorylation and this was prevented by SB (Figure 1d). In contrast, phosphorylation of c-jun N-terminal kinase (JNK), another MAPK implicated in insulin resistance, did not differ across groups (Figure 1e). In liver samples collected after clamp, phosphorylation (that is, activation) of Akt, a mediator of insulin signalling, was decreased by IH and this was prevented by SB (Figure 1f).

To corroborate our data, we used another model of prolonged (48 h) lipid infusion, combined ethylethanol plus ethylpalmitate infusion with or without SB in mice, and found that again, SB prevented lipid-induced hepatic but not peripheral insulin resistance (Figure 2).

DISCUSSION

We found herein that the p38 MAPK inhibitor SB239063 prevented hepatic insulin resistance caused by prolonged plasma FFA elevation in rats. This effect was associated with decreased activation of ATF2, a direct target of p38 MAPK, in the liver. We confirmed the benefits of SB239063 on lipid-induced hepatic insulin resistance in mice infused with combined ethylethanol plus ethylpalmitate. SB239063, however, did not have beneficial effects on peripheral insulin sensitivity.

To our knowledge, this is the first study to show that inhibition of p38 MAPK prevents hepatic insulin resistance caused by FFAs in vivo. The role of p38 MAPK in FFA-induced hepatic insulin resistance has been studied in hepatocytes,5 where p38 MAPK stabilized PTEN (protein phosphatase and tensin homolog deleted on chromosome 10), an antagonist of the effects of phosphoinositide 3-kinase.4 Akt is downstream of phosphoinositide 3-kinase and the current study shows that the p38 MAPK inhibitor prevents IH-induced impairment in hepatic Akt activation. FFA-induced p38 MAPK activation also increases gluconeogenic gene transcription,6 which may explain the trend toward increased basal endogenous glucose production by IH, abolished by SB239063.

IH increased ATF2 phosphorylation and SB239063 thwarted this, which suggests that SB239063 acts by inhibiting p38 MAPK. SB239063 inhibits both p38α MAPK and p38β MAPK7 although p38α MAPK mediated the FFA effects in hepatocytes.5,6 In contrast, activation of hepatic JNK was not altered by IH or SB239063. SB239063 did not improve peripheral insulin sensitivity. p38 MAPK is activated in muscle of humans with type 2 diabetes,10,11 and of mice following lipid infusion;12 however, p38 MAPK inhibition did not improve insulin-stimulated muscle glucose uptake.11 There are reports that SB239063 inhibits glucose uptake in muscle cell lines13 perhaps independent of p38 MAPK,14 and our results suggest that SB239063 alone decreased glucose utilization in vivo. However, the percent augmentation in glucose utilization by insulin infusion did not differ in SB239063 vs SAL.

In conclusion, in our models of prolonged lipid infusion, inhibition of p38 MAPK ameliorates hepatic insulin sensitivity. As prolonged lipid infusion activates liver PKC-δ6 and PKC-δ activates p38 MAPK in hepatocytes,5 PKC-δ may be upstream of p38 MAPK in FFA-induced hepatic insulin resistance in vivo, but this remains to be determined. The reason why p38 MAPK inhibition is effective on FFA-induced hepatic but not peripheral insulin resistance is unclear; however, there are different possibilities, including different mechanisms of insulin resistance in the periphery vs liver after 48 h IH16 and a possible adverse effect of SB239063 on glucose utilization.

As some MAPK inhibitors can be used in humans and are in phase II clinical trials for their antinflammatory and antineoplastic properties,17–19 it would be of interest to determine whether these inhibitors can improve obesity-associated hepatic insulin resistance.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We thank Loretta Lam for technical assistance. SP was funded by Doctoral Award from CIHR, Ontario Graduate Scholarship (OGS), and Bantering and Best Diabetes Centre Studentship. WQY was funded by OGS and YM by a Showa University Grant for Young Researchers. The study was funded by a research grant to AG from the Canadian Institutes of Health Research (CIHR) (MOP-89929, 2008-2013 entitled ‘Mechanisms of hepatic insulin resistance in vivo’).

REFERENCES

1 Boden G, She P, Mozelli M, Cheung P, Gumireddy K, Reddy P et al. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-κappaB pathway in rat liver. Diabetologia 2005; 54/12: 3458–3465.

2 Lam TK, van de Werve G, Giacca A. Free fatty acids increase basal hepatic glucose production and induce hepatic insulin resistance at different sites. Am J Physiol Endocrinol Metab 2003; 284/2: E281–E290.

3 Pereira S, Yu WQ, Frigolet ME, Beaudry JL, Shipilberg Y, Park E et al. Duration of rise in free fatty acids determines salicylate’s effect on hepatic insulin sensitivity. J Endocrinol 2013; 217/1: 31–43.
4 Liu HY, Collins QF, Xiong Y, Moukdar F, Lupo Jr EG, Liu Z et al. Prolonged treatment of primary hepatocytes with oleate induces insulin resistance through p38 mitogen-activated protein kinase. J Biol Chem 2007; 282/19: 14205–14212.

5 Hemi R, Yochananov Y, Barhod E, Kasher-Meron M, Karasik A, Tirosch A et al. p38 mitogen-activated protein kinase-dependent transactivation of ErbB receptor family: a novel common mechanism for stress-induced IRS-1 serine phosphorylation and insulin resistance. Diabetes 2011; 60/4: 1134–1145.

6 Collins QF, Xiong Y, Lupo Jr EG, Liu HY, Cao W. p38 Mitogen-activated protein kinase mediates free fatty acid-induced gluconeogenesis in hepatocytes. J Biol Chem 2006; 281/34: 24336–24344.

7 Barone FC, Irving EA, Ray AM, Lee JC, Kassis S, Kumar S et al. SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. J Pharmacol Exp Ther 2001; 296/2: 312–321.

8 Eguchi K, Manabe I, Oishi-Tanaka Y, Ohsugi M, Kono N, Ogata F et al. Saturated fatty acid and TLR signaling link beta cell dysfunction and islet inflammation. Cell Metab 2012; 15/4: 518–533.

9 Naimi M, Tsakiridis T, Stamatatos TC, Alexandropoulos DI, Tsiani E. Increased skeletal muscle glucose uptake by rosemary extract through AMPK activation. Appl Physiol Nutr Metab 2015; 40/4: 407–413.

10 Koistinen HA, Chibalin AV, Zierath JR. Aberrant p38 mitogen-activated protein kinase signalling in skeletal muscle from Type 2 diabetic patients. Diabetologia 2003; 46/10: 1324–1328.

11 Brown AE, Palsgaard J, Borup R, Avery P, Gunn DA, De Meyts P et al. p38 MAPK activation upregulates proinflammatory pathways in skeletal muscle cells from insulin-resistant type 2 diabetic patients. Am J Physiol Endocrinol Metab 2015; 308: E63–E70.

12 Kim BS, Cha HN, Kim YW, Kim JY, Dan JM, Park SY. Inhibition of lipid infusion-induced skeletal muscle insulin resistance by cotreatment with tempol and glutathione in mice. J Pharmacol Sci 2009; 110/3: 370–380.

13 Somwar R, Kim DY, Sweeney G, Huang C, Niu W, Lador C et al. GLUT4 translocation precedes the stimulation of glucose uptake by insulin in muscle cells: potential activation of GLUT4 via p38 mitogen-activated protein kinase. Biochem J 2001; 359: 639–649.

14 Turban S, Beardmore VA, Carr JM, Sakamoto K, Hajduch E, Arthur JS et al. Insulin-stimulated glucose uptake does not require p38 mitogen-activated protein kinase in adipose tissue or skeletal muscle. Diabetes 2005; 54: 3161–3168.

15 Lee J, Sun C, Zhou Y, Lee J, Gokpal D, Herrema H et al. p38 MAPK-mediated regulation of Xbp1s is crucial for glucose homeostasis. Nat Med 2011; 17/10: 1251–1260.

16 Pereira S, Shah A, Fantus I, Joseph JW, Giacca A. Effect of N-acetyl-L-cysteine on insulin resistance caused by prolonged free fatty acid elevation. J Endocrinol 2015; 225/1: 1–7.

17 Lomas DA, Lipson DA, Miller BE, Willits L, Keene O, Barnacle H et al. Losmapimod Study Investigators: an oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. J Clin Pharmacol 2012; 52: 416–424.

18 Melloni C, Sprecher DL, Sarov-Blat L, Patel MR, Heitner JF, Hamm CW et al. The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale. Am Heart J 2012; 164/5: 646–653.

19 Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P et al. Randomized, dose-escalation study of the p38alpha MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome. Leukemia 2013; 27/4: 977–980.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/